Payment overview · 2025
General Payments
$20,921.68
185 reported records · 31 companies
Healthcare provider profile · identity verified
Rahul Malhotra, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · GLENDALE, AZ · NPI 1629079876
Verified facts
What the public records show
CMS Open Payments records show Rahul Malhotra, MD received $20,921.68 in general payments during 2025 across 185 reported records.
Medtronic, Inc. accounted for 51.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 51 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Verquvo.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 238 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 360 claims for Eliquis by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 360 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$10,795.01 | 51.6% | 26 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $3,149.09 | 15.1% | 10 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $2,656.27 | 12.7% | 33 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $1,539.21 | 7.4% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $309.36 | 1.5% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $259.22 | 1.2% | 12 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $232.12 | 1.1% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $229.50 | 1.1% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $200.37 | 1.0% | 20 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $192.97 | 0.9% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $181.90 | 0.9% | 9 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $154.06 | 0.7% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $147.55 | 0.7% | 7 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $125.00 | 0.6% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $86.99 | 0.4% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $79.90 | 0.4% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $73.04 | 0.3% | 4 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $66.77 | 0.3% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $50.57 | 0.2% | 2 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $49.25 | 0.2% | 2 | 2025 |
| Siemens Medical Solutions USA, Inc. | Unresolved — no canonical attribution shown | $48.53 | 0.2% | 1 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $46.30 | 0.2% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $41.60 | 0.2% | 2 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $36.29 | 0.2% | 1 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $34.83 | 0.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.75 | 0.2% | 2 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $28.22 | 0.1% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $24.81 | 0.1% | 1 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $21.21 | 0.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.80 | 0.1% | 1 | 2025 |
| Advanced Oxygen Therapy Inc. | Unresolved — no canonical attribution shown | $13.19 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $11,175.82 | 11 |
| Food and Beverage | $8,145.86 | 173 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,600.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $3,149.09 | 10 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $1,883.29 | 9 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $1,391.09 | 9 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $1,391.09 | 9 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $659.61 | 10 | 2025 |
Source payment records
|
|||||
| General - Brady Normalized: general brady |
Device | Boston Scientific Corporation | $277.84 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $259.22 | 12 | 2025 |
Source payment records
|
|||||
| EkoSonic Normalized: ekosonic |
Device | Boston Scientific Corporation | $247.09 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $200.37 | 20 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $192.97 | 9 | 2025 |
Source payment records
|
|||||
| TURBOHAWK Normalized: turbohawk |
Device | Medtronic, Inc. | $182.77 | 2 | 2025 |
Source payment records
|
|||||
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $165.38 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $164.79 | 8 | 2025 |
Source payment records
|
|||||
| LIMFLOW SYSTEM Normalized: limflow system |
Device | Stryker Corporation | $154.54 | 2 | 2025 |
Source payment records
|
|||||
| Alto Abdominal Stent Graft System Normalized: alto abdominal stent graft system |
Device | Endologix LLC | $148.12 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $147.55 | 7 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $142.20 | 11 | 2025 |
Source payment records
|
|||||
| ZILVER VENA Normalized: zilver vena |
Device | Cook Medical LLC | $136.91 | 1 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $120.22 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $98.88 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $73.04 | 4 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $66.77 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $60.21 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $50.57 | 2 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $49.25 | 2 | 2025 |
Source payment records
|
|||||
| Artis Q ceiling Normalized: artis q ceiling |
Device | Siemens Medical Solutions USA, Inc. | $48.53 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $41.60 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $36.80 | 2 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $36.29 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $36.16 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $36.16 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $33.75 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $33.50 | 1 | 2025 |
Source payment records
|
|||||
| OptiCross 35 Normalized: opticross 35 |
Device | Boston Scientific Corporation | $32.13 | 2 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $28.22 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $24.81 | 1 | 2025 |
Source payment records
|
|||||
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $23.76 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| OPTOWIRE Normalized: optowire |
Device | CARDIVA MEDICAL, INC. | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| General - Atherectomy Normalized: general atherectomy |
Device | Boston Scientific Corporation | $19.02 | 2 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| ZILVER PTX Normalized: zilver ptx |
Device | Cook Medical LLC | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| Topical Oxygen Chamber for extremities Normalized: topical oxygen chamber for extremities |
Device | Advanced Oxygen Therapy Inc. | $13.19 | 1 | 2025 |
Source payment records
|
|||||
| LithoVue Empower Normalized: lithovue empower |
Device | Boston Scientific Corporation | $11.96 | 1 | 2025 |
Source payment records
|
|||||
| General - Tachy Normalized: general tachy |
Device | Boston Scientific Corporation | $9.24 | 1 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $8.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 360 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 111 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 53 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
238 | 54 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
111 | 33 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
360 | 89 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
192 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
360 | 89 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 708 | 224 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 678 | 229 |
| Clopidogrel | Clopidogrel Bisulfate | 485 | 160 |
| Atorvastatin Calcium | Atorvastatin Calcium | 393 | 127 |
| Eliquis | Apixaban | 360 | 89 |
| Lisinopril | Lisinopril | 291 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 253 | 88 |
| Brilinta | Ticagrelor | 238 | 54 |
| Carvedilol | Carvedilol | 236 | 76 |
| Repatha Sureclick | Evolocumab | 233 | 37 |
| Entresto | Sacubitril/Valsartan | 192 | 42 |
| Ezetimibe | Ezetimibe | 191 | 69 |
| Losartan Potassium | Losartan Potassium | 176 | 63 |
| Xarelto | Rivaroxaban | 174 | 39 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 160 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 149 | 55 |
| Furosemide | Furosemide | 115 | 36 |
| Farxiga | Dapagliflozin Propanediol | 111 | 33 |
| Ranolazine Er | Ranolazine | 104 | 28 |
| Nebivolol Hcl | Nebivolol Hcl | 89 | 27 |
| Potassium Chloride | Potassium Chloride | 71 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 67 | 27 |
| Nitroglycerin | Nitroglycerin | 58 | 26 |
| Cilostazol | Cilostazol | 56 | 18 |
| Verquvo | Vericiguat | 53 | 13 |
| Flecainide Acetate | Flecainide Acetate | 51 | 15 |
| Spironolactone | Spironolactone | 47 | 16 |
| Sotalol | Sotalol Hcl | 46 | 12 |
| Chlorthalidone | Chlorthalidone | 45 | 18 |
| Warfarin Sodium | Warfarin Sodium | 44 | 11 |
| Nifedipine Er | Nifedipine | 38 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 37 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 13 |
| Midodrine Hcl | Midodrine Hcl | 33 | 11 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Praluent Pen | Alirocumab | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 26 | 12 |
| Simvastatin | Simvastatin | 25 | suppressed |
| Clonidine | Clonidine | 24 | suppressed |
| Omeprazole | Omeprazole | 20 | suppressed |
| Inpefa | Sotagliflozin | 18 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Edarbi | Azilsartan Medoxomil | 12 | suppressed |
| Allopurinol | Allopurinol | 11 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Repatha Pushtronex | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $20,921.68 · 185 records | Medtronic, Inc. | ABRE, AMPLATZER AMULET, AMVUTTRA, Alto Abdominal Stent Graft System, Artis Q ceiling, Assure WCD, Barostim Neo System, CAMZYOS, CARDIVA VASCADE MVP VVCS 6-12F, CLOTTRIEVER BOLD CATHETER, CT THROMBECTOMY SYSTEM KIT, ELIQUIS, ENDOCROSS Device, ESPRIT, EkoSonic, FARXIGA, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, General - Atherectomy, General - Brady, General - Tachy, General - Therapies, General - Vascular Intervention, INSPIRE, Indigo System, JARDIANCE, LEQVIO, LIMFLOW SYSTEM, LifeVest, LithoVue Empower, MOUNJARO, NURTEC ODT, OPSUMIT, OPTOWIRE, OptiCross 35, Paradise Ultrasound Renal Denervation System, REPATHA, SYMPHONY CATHETER, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TRICLIP, TURBOHAWK, Topical Oxygen Chamber for extremities, Torus Stent Graft System, VERQUVO, VYNDAQEL, WATCHMAN FLX, Wegovy, ZEPBOUND, ZILVER PTX, ZILVER VENA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error